Abstract：Objective To investigate the clinical effect and safety of Dapagliflozin in the treatment of newly diagnosed type 2 diabetes mellitus.Methods A total of 70 newly diagnosed type 2 diabetes mellitus patients treated in our hospital from March 2018 to June 2019 were selected as the research subjects.The patients were divided into observation group(36 cases)and control group(34 cases)according to the randomized control principle.The patients in the observation group were treated with Dapagliflozin alone,while those in the control group were treated with Metformin alone.The blood glucose indexes(fasting blood glucose[FBG],post-prandial glucosese[PBG],glycosylated hemoglobin[HbA1c])levels,body mass index(BMI),blood pressure(systolic blood pressure[SBP],diastolic blood pressure[DBP]),lipid indicators(total cholesterol[TC],triacylglycerol[TG]),liver and kidney function indicators(alanine aminotransferase[AST],aspartate aminotransferase[ALT],creatinine[Cr])levels before and after treatment and the total incidence rate of adverse reactions were compared between the two groups of patients.Results After 12 weeks of treatment,the FBG,PBG,HbA1c,and BMI of the two groups were lower than those before treatment,and the differences were statistically significant(P＜0.05).There were no significant differences in FBG,PBG,HbA1c,and BMI between the two groups after 12 weeks of treatment(P＞0.05).After 12 weeks of treatment,the SBP,TC,and TG in the observation group were lower than those before treatment,and the differences were statistically significant(P＜0.05).The SBP in the observation group was lower than that in the control group after 12 weeks of treatment,and the difference was statistically significant(P＜0.05).There was no significant hypoglycemia or allergic reaction in both groups.The total incidence rate of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion Dapagliflozin has a definite hypoglycemic effect in the treatment of newly diagnosed type 2 diabetes mellitus,and it can also improve a number of metabolic indicators,without obvious gastrointestinal reactions,and with high safety.
Ji LN，Lu JM，Guo XH，et al.Glycemic control among patients in china with type 2 diabetes mellitus receiving oral drugs or injectables[J].BMC Pubic Health，2013，21（13）：602.
[3]
Araki E，Onishi Y，Asano M，et al.Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes：results of the interim analysis of 16-week double blind treatment period[J].J Diabetes Investig，2016，7（4）：555-564.
Tosaki T，Kamiya H，Himeno T，et al.Sodium-glucose cotransporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes[J].Intern Med，2017，56（6）：597-604.
Goke B，Gallwitz B，Eriksson J，et al.Saxagliptin is non-inferior to glipizide in patients with type2 diabetes mellitus inadequately controlled on metformin alone：a 52-week randomized controlled trial[J].Int J Clin Prace，2010，64（12）：1619-1631.
[11]
Phillips P，Karrasch J，Scote R，et al.Acarbose imoroves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin[J].Diabetes Care，2003，26（2）：269-273.
[12]
Salvo F，More N，Arnaud M，et al.Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia：systematic reviem and meta-analysis[J].BMJ，2016，353：i2231.
Papakitsou I，Vougiouklakis G，Elisaf MS，et al.Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes[J].Clin Pharmacol，2019，11：133-143.
Sun YN，Zhou Y，Chen X，et al.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus：meta-analysis of randomised controlled trials[J].BMJ Open，2014，4（4）：e004619.
京公网安备 11010502046607号